Actively Recruiting
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
Led by Henan Cancer Hospital · Updated on 2025-04-23
30
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of Rituximab, Lenalidomide combined with high-dose Methotrexate and Temozolomide (RL-MT) in the first-line treatment for patients with primary central nervous system lymphoma.
CONDITIONS
Official Title
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 to 70 years old (including 18 and 70)
- Diagnosed as primary central nervous system lymphoma limited to brain, spinal cord, meninges, and eyes without other involvement
- No prior anti-tumor therapy except tumor resection, biopsy, or glucocorticoids for CNS symptoms
- At least one measurable lesion
- ECOG performance status 0-2 (ECOG 3 due to tumor allowed after full assessment)
- Life expectancy of at least 1 month
- Adequate main organ function
- Negative pregnancy test within 7 days for women of childbearing potential, with contraception during study and for 6 months after
- Signed informed consent
You will not qualify if you...
- Secondary central nervous system lymphoma
- CD20 negative large B cell primary CNS lymphoma
- Active malignant tumor requiring treatment
- History of other malignant tumors
- Serious surgery or trauma within 2 weeks
- Active tuberculosis
- Serious acute or chronic infection requiring systemic therapy
- Congestive heart failure, uncontrolled coronary heart disease, arrhythmia, or heart infarction within 6 months
- HIV-positive, AIDS, or untreated active hepatitis
- History of deep vein thrombosis or pulmonary embolism within 12 months
- History of mental illness or drug abuse
- Poor compliance during trial or follow-up
- Allergies to any trial ingredients, excipients, mouse-derived products, or heterologous proteins
- Investigator judgment of unsuitability for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
Actively Recruiting
Research Team
Z
Zhihua Yao, M.D. Ph.D
CONTACT
Y
Yanyan Liu, M.D. Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here